Clinical Trial: Helicobacter Pylori Eradication to Prevent Gastric Cancer

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial

Brief Summary: Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection appears to reduce the risk of gastric cancer. However, several recent controlled interventional trials by H. pylori eradication to prevent gastric cancer have yielded disappointing results. The exact effect of H.pylori eradication on prevention of gastric cancer is unclear up to now. To clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether H pylori eradication would reduce the incidence of gastric cancer in a high-risk population in China.

Detailed Summary:
Sponsor: Jie-Jun Wang

Current Primary Outcome: Gastric cancer incidence [ Time Frame: 10 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Histopathological changes [ Time Frame: 10 years ]

Original Secondary Outcome: Same as current

Information By: Second Military Medical University

Dates:
Date Received: May 28, 2010
Date Started: June 2010
Date Completion: May 2020
Last Updated: January 3, 2014
Last Verified: January 2014